Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma
Phase I/II Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma
Sponsor: CureTech Ltd
Terminated
The study was stopped because of slow accrual
Other terminated trials from CureTech Ltd
More terminations from CureTech Ltd
Listed as NCT00966251, this PHASE1/PHASE2 trial focuses on Primary Hepatocellular Carcinoma and remains terminated or withdrawn. Sponsored by CureTech Ltd, it has been updated 6 times since 2009, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2022 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2021 — Jan 2022 [monthly]
Terminated PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
First recorded
Oct 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CureTech Ltd
- Teva Branded Pharmaceutical Products R&D, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .